Treatment of proliferative lupus nephritis: a changing landscape.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16900218.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Grootscholten et al. report a randomized controlled trial comparing azathioprine plus intravenous methylprednisolone and oral prednisolone (AZA group) with intermittent intravenous cyclophosphamide and oral prednisolone (CY group) in patients with proliferative lupus nephritis. AZA-treated patients were more likely to develop non-sustained doubling of their serum creatinine, although not significantly so, and significantly more likely to have a relapse of their nephritis than CY-treated patients.
Medical subject headings
- Anti-Inflammatory Agents
- Azathioprine
- Cyclophosphamide
- Immunosuppressive Agents
- Lupus Nephritis
- Methylprednisolone
- Prednisolone